Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD

robot
Abstract generation in progress

Benjamin Edwards Inc. decreased its stake in Gilead Sciences, Inc. by 19.8% in Q4, now holding 135,209 shares valued at $16.6 million. This comes as Gilead has received FDA priority review for its new HIV regimen and completed a significant acquisition. Insider selling by executives, including CEO Daniel O’Day, was also noted, alongside positive analyst sentiment and recent dividend increases for the biopharmaceutical company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin